Skip to main content
Erschienen in: Abdominal Radiology 2/2017

13.09.2016 | Pictorial Essay

An overview of PET/MR, focused on clinical applications

verfasst von: Onofrio Antonio Catalano, William Roger Masch, Ciprian Catana, Umar Mahmood, Dushyant Vasudeo Sahani, Michael Stanley Gee, Leon Menezes, Andrea Soricelli, Marco Salvatore, Debra Gervais, Bruce Robert Rosen

Erschienen in: Abdominal Radiology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Hybrid PET/MR scanners are innovative imaging devices that simultaneously or sequentially acquire and fuse anatomical and functional data from magnetic resonance (MR) with metabolic information from positron emission tomography (PET) (Delso et al. in J Nucl Med 52:1914–1922, 2011; Zaidi et al. in Phys Med Biol 56:3091–3106, 2011). Hybrid PET/MR scanners have the potential to greatly impact not only on medical research but also, and more importantly, on patient management. Although their clinical applications are still under investigation, the increased worldwide availability of PET/MR scanners, and the growing published literature are important determinants in their rising utilization for primarily clinical applications. In this manuscript, we provide a summary of the physical features of PET/MR, including its limitations, which are most relevant to clinical PET/MR implementation and to interpretation. Thereafter, we discuss the most important current and emergent clinical applications of such hybrid technology in the abdomen and pelvis, both in the field of oncologic and non-oncologic imaging, and we provide, when possible, a comparison with clinically consolidated imaging techniques, like for example PET/CT.
Literatur
1.
Zurück zum Zitat Delso G, Furst S, Jakoby B, et al. (2011) Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med 52:1914–1922CrossRefPubMed Delso G, Furst S, Jakoby B, et al. (2011) Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med 52:1914–1922CrossRefPubMed
2.
Zurück zum Zitat Zaidi H, Ojha N, Morich M, et al. (2011) Design and performance evaluation of a whole-body Ingenuity TF PET-MRI system. Phys Med Biol 56:3091–3106CrossRefPubMedPubMedCentral Zaidi H, Ojha N, Morich M, et al. (2011) Design and performance evaluation of a whole-body Ingenuity TF PET-MRI system. Phys Med Biol 56:3091–3106CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Torigian DA, Zaidi H, Kwee TC, et al. (2013) PET/MR imaging: technical aspects and potential clinical applications. Radiology 267:26–44CrossRefPubMed Torigian DA, Zaidi H, Kwee TC, et al. (2013) PET/MR imaging: technical aspects and potential clinical applications. Radiology 267:26–44CrossRefPubMed
5.
Zurück zum Zitat Hofmann M, Bezrukov I, Mantlik F, et al. (2011) MRI-based attenuation correction for whole-body PET/MRI: quantitative evaluation of segmentation- and atlas-based methods. J Nucl Med 52:1392–1399CrossRefPubMed Hofmann M, Bezrukov I, Mantlik F, et al. (2011) MRI-based attenuation correction for whole-body PET/MRI: quantitative evaluation of segmentation- and atlas-based methods. J Nucl Med 52:1392–1399CrossRefPubMed
6.
Zurück zum Zitat Dickson JC, O’Meara C, Barnes A (2014) A comparison of CT- and MR-based attenuation correction in neurological PET. Eur J Nucl Med Mol Imaging 41:1176–1189CrossRefPubMed Dickson JC, O’Meara C, Barnes A (2014) A comparison of CT- and MR-based attenuation correction in neurological PET. Eur J Nucl Med Mol Imaging 41:1176–1189CrossRefPubMed
7.
Zurück zum Zitat Catana C, Drzezga A, Heiss WD, Rosen BR (2012) PET/MRI for neurologic applications. J Nucl Med 53:1916–1925CrossRefPubMed Catana C, Drzezga A, Heiss WD, Rosen BR (2012) PET/MRI for neurologic applications. J Nucl Med 53:1916–1925CrossRefPubMed
9.
Zurück zum Zitat Antoch G, Stattaus J, Nemat AT, et al. (2003) Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 229:526–533CrossRefPubMed Antoch G, Stattaus J, Nemat AT, et al. (2003) Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 229:526–533CrossRefPubMed
10.
Zurück zum Zitat Lardinois D, Weder W, Hany TF, et al. (2003) Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348:2500–2507CrossRefPubMed Lardinois D, Weder W, Hany TF, et al. (2003) Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348:2500–2507CrossRefPubMed
11.
Zurück zum Zitat Boss DS, Olmos RV, Sinaasappel M, Beijnen JH, Schellens JH (2008) Application of PET/CT in the development of novel anticancer drugs. Oncologist 13:25–38CrossRefPubMed Boss DS, Olmos RV, Sinaasappel M, Beijnen JH, Schellens JH (2008) Application of PET/CT in the development of novel anticancer drugs. Oncologist 13:25–38CrossRefPubMed
12.
Zurück zum Zitat Al-Sugair A, Coleman RE (1998) Applications of PET in lung cancer. Semin Nucl Med 28:303–319CrossRefPubMed Al-Sugair A, Coleman RE (1998) Applications of PET in lung cancer. Semin Nucl Med 28:303–319CrossRefPubMed
13.
Zurück zum Zitat Jerusalem G, Beguin Y, Najjar F, et al. (2001) Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL). Ann Oncol 12:825–830CrossRefPubMed Jerusalem G, Beguin Y, Najjar F, et al. (2001) Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL). Ann Oncol 12:825–830CrossRefPubMed
14.
Zurück zum Zitat Kayani I, Bomanji JB, Groves A, et al. (2008) Functional imaging of neuroendocrine tumors with combined PET/CT using 68 Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer 112:2447–2455CrossRefPubMed Kayani I, Bomanji JB, Groves A, et al. (2008) Functional imaging of neuroendocrine tumors with combined PET/CT using 68 Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer 112:2447–2455CrossRefPubMed
15.
Zurück zum Zitat Park JW, Kim JH, Kim SK, et al. (2008) A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 49:1912–1921CrossRefPubMed Park JW, Kim JH, Kim SK, et al. (2008) A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 49:1912–1921CrossRefPubMed
16.
Zurück zum Zitat Son H, Khan SM, Rahaman J, et al. (2011) Role of FDG PET/CT in staging of recurrent ovarian cancer. Radiographics 31:569–583CrossRefPubMed Son H, Khan SM, Rahaman J, et al. (2011) Role of FDG PET/CT in staging of recurrent ovarian cancer. Radiographics 31:569–583CrossRefPubMed
17.
Zurück zum Zitat Mueller-Lisse UG, Mueller-Lisse UL, Meindl T, et al. (2007) Staging of renal cell carcinoma. Eur Radiol 17:2268–2277CrossRefPubMed Mueller-Lisse UG, Mueller-Lisse UL, Meindl T, et al. (2007) Staging of renal cell carcinoma. Eur Radiol 17:2268–2277CrossRefPubMed
18.
Zurück zum Zitat Ozawa Y, Hara M, Sakurai K, et al. (2010) Diagnostic accuracy of (18)F-2-deoxy-fluoro-d-glucose positron emission tomography for pN2 lymph nodes in patients with lung cancer. Acta Radiol 51:150–155CrossRefPubMed Ozawa Y, Hara M, Sakurai K, et al. (2010) Diagnostic accuracy of (18)F-2-deoxy-fluoro-d-glucose positron emission tomography for pN2 lymph nodes in patients with lung cancer. Acta Radiol 51:150–155CrossRefPubMed
19.
Zurück zum Zitat Sharma P, Kumar R, Singh H, et al. (2012) Carcinoma endometrium: role of 18-FDG PET/CT for detection of suspected recurrence. Clin Nucl Med 37:649–655CrossRefPubMed Sharma P, Kumar R, Singh H, et al. (2012) Carcinoma endometrium: role of 18-FDG PET/CT for detection of suspected recurrence. Clin Nucl Med 37:649–655CrossRefPubMed
20.
Zurück zum Zitat von Schulthess GK, Schlemmer HP (2009) A look ahead: PET/MR versus PET/CT. Eur J Nucl Med Mol Imaging 36(Suppl 1):S3–S9CrossRef von Schulthess GK, Schlemmer HP (2009) A look ahead: PET/MR versus PET/CT. Eur J Nucl Med Mol Imaging 36(Suppl 1):S3–S9CrossRef
21.
Zurück zum Zitat Nasu K, Kuroki Y, Nawano S, et al. (2006) Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging. Radiology 239:122–130CrossRefPubMed Nasu K, Kuroki Y, Nawano S, et al. (2006) Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging. Radiology 239:122–130CrossRefPubMed
22.
Zurück zum Zitat Padhani AR, Koh DM, Collins DJ (2011) Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology 261:700–718CrossRefPubMed Padhani AR, Koh DM, Collins DJ (2011) Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology 261:700–718CrossRefPubMed
23.
Zurück zum Zitat Brown G, Richards CJ, Bourne MW, et al. (2003) Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology 227:371–377CrossRefPubMed Brown G, Richards CJ, Bourne MW, et al. (2003) Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology 227:371–377CrossRefPubMed
24.
Zurück zum Zitat Bruegel M, Holzapfel K, Gaa J, et al. (2008) Characterization of focal liver lesions by ADC measurements using a respiratory triggered diffusion-weighted single-shot echo-planar MR imaging technique. Eur Radiol 18:477–485CrossRefPubMed Bruegel M, Holzapfel K, Gaa J, et al. (2008) Characterization of focal liver lesions by ADC measurements using a respiratory triggered diffusion-weighted single-shot echo-planar MR imaging technique. Eur Radiol 18:477–485CrossRefPubMed
25.
Zurück zum Zitat Eiber M, Beer AJ, Holzapfel K, et al. (2010) Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging. Invest Radiol 45:15–23CrossRefPubMed Eiber M, Beer AJ, Holzapfel K, et al. (2010) Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging. Invest Radiol 45:15–23CrossRefPubMed
26.
Zurück zum Zitat Fornasa F, Nesoti MV, Bovo C, Bonavina MG (2012) Diffusion-weighted magnetic resonance imaging in the characterization of axillary lymph nodes in patients with breast cancer. J Magn Reson Imaging 36:858–864CrossRefPubMed Fornasa F, Nesoti MV, Bovo C, Bonavina MG (2012) Diffusion-weighted magnetic resonance imaging in the characterization of axillary lymph nodes in patients with breast cancer. J Magn Reson Imaging 36:858–864CrossRefPubMed
27.
Zurück zum Zitat De Iaco P, Musto A, Orazi L, et al. (2011) FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy. Eur J Radiol 80:e98–e103CrossRefPubMed De Iaco P, Musto A, Orazi L, et al. (2011) FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy. Eur J Radiol 80:e98–e103CrossRefPubMed
28.
Zurück zum Zitat Soussan M, Des Guetz G, Barrau V, et al. (2012) Comparison of FDG-PET/CT and MR with diffusion-weighted imaging for assessing peritoneal carcinomatosis from gastrointestinal malignancy. Eur Radiol 22:1479–1487CrossRefPubMed Soussan M, Des Guetz G, Barrau V, et al. (2012) Comparison of FDG-PET/CT and MR with diffusion-weighted imaging for assessing peritoneal carcinomatosis from gastrointestinal malignancy. Eur Radiol 22:1479–1487CrossRefPubMed
29.
Zurück zum Zitat De Gaetano AM, Calcagni ML, Rufini V, et al. (2009) Imaging of peritoneal carcinomatosis with FDG PET-CT: diagnostic patterns, case examples and pitfalls. Abdom Imaging 34:391–402CrossRefPubMed De Gaetano AM, Calcagni ML, Rufini V, et al. (2009) Imaging of peritoneal carcinomatosis with FDG PET-CT: diagnostic patterns, case examples and pitfalls. Abdom Imaging 34:391–402CrossRefPubMed
30.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed Eisenhauer EA, Therasse P, Bogaerts J, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed
31.
Zurück zum Zitat Kirchner J, Kirchner EM, Goltz JP, Lorenz VW, Kickuth R (2011) Prevalence of enlarged mediastinal lymph nodes in heavy smokers–a comparative study. Eur Radiol 21:1594–1599CrossRefPubMed Kirchner J, Kirchner EM, Goltz JP, Lorenz VW, Kickuth R (2011) Prevalence of enlarged mediastinal lymph nodes in heavy smokers–a comparative study. Eur Radiol 21:1594–1599CrossRefPubMed
32.
Zurück zum Zitat Atkinson W, Catana C, Abramson JS, et al. (2016) Hybrid FDG-PET/MR compared to FDG-PET/CT in adult lymphoma patients. Abdom Radiol 41:1338–1348CrossRef Atkinson W, Catana C, Abramson JS, et al. (2016) Hybrid FDG-PET/MR compared to FDG-PET/CT in adult lymphoma patients. Abdom Radiol 41:1338–1348CrossRef
33.
Zurück zum Zitat Heacock L, Weissbrot J, Raad R, et al. (2015) PET/MRI for the evaluation of patients with lymphoma: initial observations. Am J Roentgenol 204:842–848CrossRef Heacock L, Weissbrot J, Raad R, et al. (2015) PET/MRI for the evaluation of patients with lymphoma: initial observations. Am J Roentgenol 204:842–848CrossRef
34.
Zurück zum Zitat Ponisio MR, McConathy J, Laforest R, Khanna G (2016) Evaluation of diagnostic performance of whole-body simultaneous PET/MRI in pediatric lymphoma. Pediatric Radiol 46:1258–1268CrossRef Ponisio MR, McConathy J, Laforest R, Khanna G (2016) Evaluation of diagnostic performance of whole-body simultaneous PET/MRI in pediatric lymphoma. Pediatric Radiol 46:1258–1268CrossRef
35.
Zurück zum Zitat Park JM, Kim IY, Kim SW, et al. (2013) A comparative study of FDG PET/CT and enhanced multi-detector CT for detecting liver metastasis according to the size and location. Ann Nucl Med 27:217–224CrossRefPubMed Park JM, Kim IY, Kim SW, et al. (2013) A comparative study of FDG PET/CT and enhanced multi-detector CT for detecting liver metastasis according to the size and location. Ann Nucl Med 27:217–224CrossRefPubMed
36.
Zurück zum Zitat Holalkere NS, Sahani DV, Blake MA, et al. (2006) Characterization of small liver lesions: Added role of MR after MDCT. J Comput Assist Tomogr 30:591–596CrossRefPubMed Holalkere NS, Sahani DV, Blake MA, et al. (2006) Characterization of small liver lesions: Added role of MR after MDCT. J Comput Assist Tomogr 30:591–596CrossRefPubMed
37.
Zurück zum Zitat Barker DW, Zagoria RJ, Morton KA, Kavanagh PV, Shen P (2005) Evaluation of liver metastases after radiofrequency ablation: utility of 18F-FDG PET and PET/CT. Am J Roentgenol 184:1096–1102CrossRef Barker DW, Zagoria RJ, Morton KA, Kavanagh PV, Shen P (2005) Evaluation of liver metastases after radiofrequency ablation: utility of 18F-FDG PET and PET/CT. Am J Roentgenol 184:1096–1102CrossRef
38.
Zurück zum Zitat Kamholtz R, Sze G (1991) Current imaging in spinal metastatic disease. Semin Oncol 18:158–169PubMed Kamholtz R, Sze G (1991) Current imaging in spinal metastatic disease. Semin Oncol 18:158–169PubMed
39.
Zurück zum Zitat Nakai T, Okuyama C, Kubota T, et al. (2005) Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 32:1253–1258CrossRefPubMed Nakai T, Okuyama C, Kubota T, et al. (2005) Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 32:1253–1258CrossRefPubMed
40.
Zurück zum Zitat Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT (2004) Bone imaging in metastatic breast cancer. J Clin Oncol 22:2942–2953CrossRefPubMed Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT (2004) Bone imaging in metastatic breast cancer. J Clin Oncol 22:2942–2953CrossRefPubMed
41.
Zurück zum Zitat Sugawara Y, Fisher SJ, Zasadny KR, et al. (1998) Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol 16:173–180CrossRefPubMed Sugawara Y, Fisher SJ, Zasadny KR, et al. (1998) Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol 16:173–180CrossRefPubMed
42.
Zurück zum Zitat Even-Sapir E, Metser U, Flusser G, et al. (2004) Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med 45:272–278PubMed Even-Sapir E, Metser U, Flusser G, et al. (2004) Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med 45:272–278PubMed
43.
Zurück zum Zitat Damle NA, Bal C, Bandopadhyaya GP, et al. (2013) The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99 mTc-MDP bone scan. Jpn J Radiol 31:262–269CrossRefPubMed Damle NA, Bal C, Bandopadhyaya GP, et al. (2013) The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99 mTc-MDP bone scan. Jpn J Radiol 31:262–269CrossRefPubMed
44.
Zurück zum Zitat Schmidt GP, Reiser MF, Baur-Melnyk A (2007) Whole-body imaging of the musculoskeletal system: the value of MR imaging. Skeletal Radiol 36:1109–1119CrossRefPubMedPubMedCentral Schmidt GP, Reiser MF, Baur-Melnyk A (2007) Whole-body imaging of the musculoskeletal system: the value of MR imaging. Skeletal Radiol 36:1109–1119CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Lecouvet FE, El Mouedden J, Collette L, et al. (2012) Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 62:68–75CrossRefPubMed Lecouvet FE, El Mouedden J, Collette L, et al. (2012) Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 62:68–75CrossRefPubMed
46.
Zurück zum Zitat Ferraro R, Agarwal A, Martin-Macintosh EL, Peller PJ, Subramaniam RM (2015) MR imaging and PET/CT in diagnosis and management of multiple myeloma. Radiographics 35:438–454CrossRefPubMed Ferraro R, Agarwal A, Martin-Macintosh EL, Peller PJ, Subramaniam RM (2015) MR imaging and PET/CT in diagnosis and management of multiple myeloma. Radiographics 35:438–454CrossRefPubMed
47.
Zurück zum Zitat Moulopoulos LA, Dimopoulos MA, Alexanian R, Leeds NE, Libshitz HI (1994) Multiple myeloma: MR patterns of response to treatment. Radiology 193:441–446CrossRefPubMed Moulopoulos LA, Dimopoulos MA, Alexanian R, Leeds NE, Libshitz HI (1994) Multiple myeloma: MR patterns of response to treatment. Radiology 193:441–446CrossRefPubMed
48.
Zurück zum Zitat Agarwal A, Chirindel A, Shah BA, Subramaniam RM (2013) Evolving role of FDG PET/CT in multiple myeloma imaging and management. Am J Roentgenol 200:884–890CrossRef Agarwal A, Chirindel A, Shah BA, Subramaniam RM (2013) Evolving role of FDG PET/CT in multiple myeloma imaging and management. Am J Roentgenol 200:884–890CrossRef
49.
Zurück zum Zitat Schoder H, Larson SM (2004) Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 34:274–292CrossRefPubMed Schoder H, Larson SM (2004) Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 34:274–292CrossRefPubMed
50.
Zurück zum Zitat Kim DJ, Kim JH, Ryu YH, et al. (2011) Nodal staging of rectal cancer: high-resolution pelvic MRI versus (1)(8)F-FDGPET/CT. J Comput Assist Tomogr 35:531–534CrossRefPubMed Kim DJ, Kim JH, Ryu YH, et al. (2011) Nodal staging of rectal cancer: high-resolution pelvic MRI versus (1)(8)F-FDGPET/CT. J Comput Assist Tomogr 35:531–534CrossRefPubMed
51.
Zurück zum Zitat Kim SH, Choi BI, Han JK, et al. (1993) Preoperative staging of uterine cervical carcinoma: comparison of CT and MRI in 99 patients. J Comput Assist Tomogr 17:633–640CrossRefPubMed Kim SH, Choi BI, Han JK, et al. (1993) Preoperative staging of uterine cervical carcinoma: comparison of CT and MRI in 99 patients. J Comput Assist Tomogr 17:633–640CrossRefPubMed
52.
Zurück zum Zitat Kim DJ, Kim JH, Lim JS, et al. (2010) Restaging of rectal cancer with MR imaging after concurrent chemotherapy and radiation therapy. Radiographics 30:503–516CrossRefPubMed Kim DJ, Kim JH, Lim JS, et al. (2010) Restaging of rectal cancer with MR imaging after concurrent chemotherapy and radiation therapy. Radiographics 30:503–516CrossRefPubMed
53.
Zurück zum Zitat Stolzmann P, Veit-Haibach P, Chuck N, et al. (2013) Detection rate, location, and size of pulmonary nodules in trimodality PET/CT-MR: comparison of low-dose CT and Dixon-based MR imaging. Invest Radiol 48:241–246CrossRefPubMed Stolzmann P, Veit-Haibach P, Chuck N, et al. (2013) Detection rate, location, and size of pulmonary nodules in trimodality PET/CT-MR: comparison of low-dose CT and Dixon-based MR imaging. Invest Radiol 48:241–246CrossRefPubMed
54.
Zurück zum Zitat Catalano OA, Rosen BR, Sahani DV, et al. (2013) Clinical impact of PET/mr imaging in patients with cancer undergoing same-day PET/CT: initial experience in 134 patients—a hypothesis-generating exploratory study. Radiology 269(3):857–8692013CrossRefPubMed Catalano OA, Rosen BR, Sahani DV, et al. (2013) Clinical impact of PET/mr imaging in patients with cancer undergoing same-day PET/CT: initial experience in 134 patients—a hypothesis-generating exploratory study. Radiology 269(3):857–8692013CrossRefPubMed
55.
Zurück zum Zitat Hirsch FW, Sattler B, Sorge I, et al. (2013) PET/MR in children. Initial clinical experience in paediatric oncology using an integrated PET/MR scanner. Pediatr Radiol 43:860–875CrossRefPubMedPubMedCentral Hirsch FW, Sattler B, Sorge I, et al. (2013) PET/MR in children. Initial clinical experience in paediatric oncology using an integrated PET/MR scanner. Pediatr Radiol 43:860–875CrossRefPubMedPubMedCentral
56.
Zurück zum Zitat Schafer JF, Gatidis S, Schmidt H, et al. (2014) Simultaneous whole-body PET/MR imaging in comparison to PET/CT in pediatric oncology: initial results. Radiology 273:220–231CrossRefPubMed Schafer JF, Gatidis S, Schmidt H, et al. (2014) Simultaneous whole-body PET/MR imaging in comparison to PET/CT in pediatric oncology: initial results. Radiology 273:220–231CrossRefPubMed
57.
Zurück zum Zitat Pugmire BS, Guimaraes AR, Lim R, et al. (2016) Simultaneous whole body (18)F-fluorodeoxyglucose positron emission tomography magnetic resonance imaging for evaluation of pediatric cancer: preliminary experience and comparison with (18)F-fluorodeoxyglucose positron emission tomography computed tomography. World J Radiol 8:322–330CrossRefPubMedPubMedCentral Pugmire BS, Guimaraes AR, Lim R, et al. (2016) Simultaneous whole body (18)F-fluorodeoxyglucose positron emission tomography magnetic resonance imaging for evaluation of pediatric cancer: preliminary experience and comparison with (18)F-fluorodeoxyglucose positron emission tomography computed tomography. World J Radiol 8:322–330CrossRefPubMedPubMedCentral
58.
Zurück zum Zitat Miglioretti DL, Johnson E, Williams A, et al. (2013) The use of computed tomography in pediatrics and the associated radiation exposure and estimated cancer risk. JAMA Pediatr 167:700–707CrossRefPubMedPubMedCentral Miglioretti DL, Johnson E, Williams A, et al. (2013) The use of computed tomography in pediatrics and the associated radiation exposure and estimated cancer risk. JAMA Pediatr 167:700–707CrossRefPubMedPubMedCentral
59.
Zurück zum Zitat Shinagare AB, Sahni VA, Sadow CA, Erturk SM, Silverman SG (2011) Feasibility of low-tube-voltage excretory phase images during CT urography: assessment using a dual-energy CT scanner. Am J Roentgenol 197:1146–1151CrossRef Shinagare AB, Sahni VA, Sadow CA, Erturk SM, Silverman SG (2011) Feasibility of low-tube-voltage excretory phase images during CT urography: assessment using a dual-energy CT scanner. Am J Roentgenol 197:1146–1151CrossRef
60.
Zurück zum Zitat Catalano OA, Gee MS, Nicolai E, et al. (2016) Evaluation of quantitative PET/MR enterography biomarkers for discrimination of inflammatory strictures from fibrotic strictures in crohn disease. Radiology 278:792–800CrossRefPubMed Catalano OA, Gee MS, Nicolai E, et al. (2016) Evaluation of quantitative PET/MR enterography biomarkers for discrimination of inflammatory strictures from fibrotic strictures in crohn disease. Radiology 278:792–800CrossRefPubMed
61.
Zurück zum Zitat Pellino G, Nicolai E, Catalano OA, et al. (2016) PET/MR versus PET/CT imaging: impact on the clinical management of small-bowel Crohn’s disease. J Crohns Colitis 10:277–285CrossRefPubMed Pellino G, Nicolai E, Catalano OA, et al. (2016) PET/MR versus PET/CT imaging: impact on the clinical management of small-bowel Crohn’s disease. J Crohns Colitis 10:277–285CrossRefPubMed
Metadaten
Titel
An overview of PET/MR, focused on clinical applications
verfasst von
Onofrio Antonio Catalano
William Roger Masch
Ciprian Catana
Umar Mahmood
Dushyant Vasudeo Sahani
Michael Stanley Gee
Leon Menezes
Andrea Soricelli
Marco Salvatore
Debra Gervais
Bruce Robert Rosen
Publikationsdatum
13.09.2016
Verlag
Springer US
Erschienen in
Abdominal Radiology / Ausgabe 2/2017
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-016-0894-5

Weitere Artikel der Ausgabe 2/2017

Abdominal Radiology 2/2017 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.